Cargando…

Characterization of resistant MCF-7 breast cancer cells developed by repeated cycles of photodynamic therapy

Breast cancer mainly affects women and causes a severe global threat to health. It is often managed and treated with surgery, chemotherapy, immunotherapy, and radiation therapy. Generally, chemotherapy as a treatment option is often opposed by responsive tumor relapse and development of resistance,...

Descripción completa

Detalles Bibliográficos
Autores principales: Aniogo, Eric Chekwube, George, Blassan P., Abrahamse, Heidi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9523167/
https://www.ncbi.nlm.nih.gov/pubmed/36188530
http://dx.doi.org/10.3389/fphar.2022.964141
_version_ 1784800212174241792
author Aniogo, Eric Chekwube
George, Blassan P.
Abrahamse, Heidi
author_facet Aniogo, Eric Chekwube
George, Blassan P.
Abrahamse, Heidi
author_sort Aniogo, Eric Chekwube
collection PubMed
description Breast cancer mainly affects women and causes a severe global threat to health. It is often managed and treated with surgery, chemotherapy, immunotherapy, and radiation therapy. Generally, chemotherapy as a treatment option is often opposed by responsive tumor relapse and development of resistance, a significant setback of current treatment. Photodynamic therapy (PDT) offers a promising modality that can treat cancer by combining a photosensitizer and laser irradiation in the presence of oxygen. However, one problem of PDT in treating breast cancer is the apparition of the resistant cell population. Thus, we aimed for stepwise selection and characterization of MCF-7 cells resistant to PDT with a sulfonated zinc phthalocyanine (ZnPcS4) photosensitizer. The wild-type MCF-7 was exposed to successive cycles of ZnPcS4-PDT, and 10resistant populations were finally obtained. In wild-type and parental cells, we analyzed the cell morphology (light microscopy), cell cycle (BrdU staining), cell viability (MTT assay), antioxidant activity (superoxide dismutase measurement), and immunofluorescence expression of resistant p-glycoprotein (P-gp). The results indicate that resistant cells showed a mesenchymal cell phenotype, few differences in antioxidant activity, an increased DNA synthesis, and more expression of P-gp than the wild-type parental cells. These distinctive features of resistant cells can provide insight into the emergence of MCF-7 cell resistance to PDT, which was necessary to design the best therapeutic procedure for improved efficacy.
format Online
Article
Text
id pubmed-9523167
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95231672022-10-01 Characterization of resistant MCF-7 breast cancer cells developed by repeated cycles of photodynamic therapy Aniogo, Eric Chekwube George, Blassan P. Abrahamse, Heidi Front Pharmacol Pharmacology Breast cancer mainly affects women and causes a severe global threat to health. It is often managed and treated with surgery, chemotherapy, immunotherapy, and radiation therapy. Generally, chemotherapy as a treatment option is often opposed by responsive tumor relapse and development of resistance, a significant setback of current treatment. Photodynamic therapy (PDT) offers a promising modality that can treat cancer by combining a photosensitizer and laser irradiation in the presence of oxygen. However, one problem of PDT in treating breast cancer is the apparition of the resistant cell population. Thus, we aimed for stepwise selection and characterization of MCF-7 cells resistant to PDT with a sulfonated zinc phthalocyanine (ZnPcS4) photosensitizer. The wild-type MCF-7 was exposed to successive cycles of ZnPcS4-PDT, and 10resistant populations were finally obtained. In wild-type and parental cells, we analyzed the cell morphology (light microscopy), cell cycle (BrdU staining), cell viability (MTT assay), antioxidant activity (superoxide dismutase measurement), and immunofluorescence expression of resistant p-glycoprotein (P-gp). The results indicate that resistant cells showed a mesenchymal cell phenotype, few differences in antioxidant activity, an increased DNA synthesis, and more expression of P-gp than the wild-type parental cells. These distinctive features of resistant cells can provide insight into the emergence of MCF-7 cell resistance to PDT, which was necessary to design the best therapeutic procedure for improved efficacy. Frontiers Media S.A. 2022-09-16 /pmc/articles/PMC9523167/ /pubmed/36188530 http://dx.doi.org/10.3389/fphar.2022.964141 Text en Copyright © 2022 Aniogo, George and Abrahamse. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Aniogo, Eric Chekwube
George, Blassan P.
Abrahamse, Heidi
Characterization of resistant MCF-7 breast cancer cells developed by repeated cycles of photodynamic therapy
title Characterization of resistant MCF-7 breast cancer cells developed by repeated cycles of photodynamic therapy
title_full Characterization of resistant MCF-7 breast cancer cells developed by repeated cycles of photodynamic therapy
title_fullStr Characterization of resistant MCF-7 breast cancer cells developed by repeated cycles of photodynamic therapy
title_full_unstemmed Characterization of resistant MCF-7 breast cancer cells developed by repeated cycles of photodynamic therapy
title_short Characterization of resistant MCF-7 breast cancer cells developed by repeated cycles of photodynamic therapy
title_sort characterization of resistant mcf-7 breast cancer cells developed by repeated cycles of photodynamic therapy
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9523167/
https://www.ncbi.nlm.nih.gov/pubmed/36188530
http://dx.doi.org/10.3389/fphar.2022.964141
work_keys_str_mv AT aniogoericchekwube characterizationofresistantmcf7breastcancercellsdevelopedbyrepeatedcyclesofphotodynamictherapy
AT georgeblassanp characterizationofresistantmcf7breastcancercellsdevelopedbyrepeatedcyclesofphotodynamictherapy
AT abrahamseheidi characterizationofresistantmcf7breastcancercellsdevelopedbyrepeatedcyclesofphotodynamictherapy